India, Nov. 3 -- Madrigal Pharmaceuticals, Inc. (MDGL) reported Tuesday a third-quarter profit, reversing a year-earlier loss, as Rezdiffra sales increased and research and development expenses declined.
Company Profile
Madrigal develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure.
Its Rezdiffra, or resmetirom, is a once-daily oral, liver-directed thyroid hormone receptor-beta agonist approved in the U.S. and European Union for MASH with moderate-to-advanced fibrosis.
Third Quarter FY26 Financial Highlights
For the quarter ended September 30, 2026, net income totaled $55.44 million, or $1.83 per diluted share, compared with a net loss of $114.1...